Results for tag: "Brentuximab Vedotin"

Brentuximab Vedotin is a targeted therapy used to treat certain types of Leukemia. It is a monoclonal antibody-drug conjugate, meaning it is composed of an antibody that binds to a specific target on cancer cells and a chemotherapy drug that is released once the antibody binds. It is used to treat Hodgkin lymphoma and systemic anaplastic large cell lymphoma, two types of cancer that affect the lymphatic system. It is also used to treat cutaneous T-cell lymphoma, a type of cancer that affects the skin. Brentuximab Vedotin is administered intravenously and is usually given in combination with other chemotherapy drugs. It works by targeting a protein called CD30, which is found on the surface of cancer cells. The antibody binds to the CD30 protein and delivers the chemotherapy drug directly to the cancer cells, killing them. Brentuximab Vedotin is marketed by several companies, including Seattle Genetics, Takeda Pharmaceuticals, and Pfizer. Show Less Read more